Latest Contracts News

Imricor Medical Systems reported a sharp 52% revenue decline and a 92% increase in net loss for H1 2025, offset by a $42.8 million equity raise boosting liquidity. The company is investing heavily in European sales and clinical trials while pursuing FDA approval.

PRL Global Ltd reported a robust 16.8% revenue increase to $1.48 billion for the year ended June 2025, yet net profit after tax plunged by over 50%, prompting a cautious dividend outlook.

Pointerra Limited reported a strong FY25 with revenue up 45% to A$11 million and a significant reduction in net loss by 68%, driven by scalable SaaS growth and key US contract wins.

Cedar Woods Properties has reported a robust 19% rise in net profit for FY25, surpassing guidance with strong presales and strategic partnerships setting the stage for continued growth.

AUB Group has reported a robust FY25 with a 17% rise in underlying net profit after tax and increased dividends, setting an optimistic tone for FY26 with growth guidance up to 13.4%.

NZME Limited reported a 3.1% revenue decline for H1 2025 but delivered a 12% rise in operating EBITDA, driven by digital growth and cost efficiencies. The company declared a 3 cent interim dividend amid ongoing economic challenges.

Genesis Energy reported a robust FY25 with a 14% rise in normalised EBITDAF and a 29% jump in net profit, driven by strategic portfolio flexibility amid volatile energy markets. The company accelerated its Gen35 strategy, including key renewable projects and long-term capacity contracts to bolster New Zealand’s energy security.

Acrow Limited reports a record FY25 with sales up 23%, driven by an 83% jump in its Industrial Access division, now half of group revenue. Despite soft formwork markets, strategic acquisitions and growth initiatives underpin a confident outlook.

Acrow Limited reported a 23% revenue increase to $265.1 million for FY25, driven by strong growth in its Industrial Access division and key acquisitions. Despite a slight dip in earnings per share, the company declared a fully franked final dividend of 2.95 cents per share.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

Symal Group Limited reported a robust FY25 with revenue and earnings growth exceeding Prospectus forecasts, underpinned by strategic acquisitions and a strong pipeline of contracts.

Symal Group has outperformed its FY25 earnings forecasts, driven by strong project margins and strategic acquisitions, setting a robust foundation for FY26 growth.